Delivering early phase clinical trials and translational research. The ECMC focus is on the delivery of early phase clinical trials and facilitating translational studies. The clinical trials team have a strong reputation for its high quality trial management and data collection with emphasis on patient safety, attracting studies specifically to Edinburgh. Our team is composed of clinical and research leads, research nurses, data managers and IT developers. The Edinburgh ECMC operates in close cooperation with Glasgow ECMC to unify molecular testing and patient allocation to studies, as a whole-Scotland approach to patients accessing Phase I trials. Our current priorities, include: First-in-human drug development Improving treatments for brain cancer Targeting molecular sub-types of ovarian cancer Cancer immunotherapy Personalisation of radiotherapy Haematological malignancies Prevention and early detection The underlying scientific activities associated with early phase clinical studies include multiomic characterisation of tumour samples at genomic, transcriptomic and protein levels, tumour imaging and pathology studies, cancer data science activities, immuno-oncology (including kinase inhibitor combinations), tumour evolution and resistance to standard and novel therapies, and bio-markers: PK, PD, response and resistance prediction. ECMC studies and clinical trials that involve tissue collection work closely with the Institute of Genetics and Cancer Host and Tumour Profiling Unit (HTPU). ECMC plays also important role in supporting the training and development of future leaders in experimental cancer medicine. This article was published on 2024-09-23
